Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
- PMID: 29317810
- PMCID: PMC5743110
- DOI: 10.2147/COPD.S145573
Inhaled therapies in patients with moderate COPD in clinical practice: current thinking
Abstract
COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups.
Keywords: LABA; LAMA; anticholinergic; dual bronchodilation; inhaled corticosteroid; tiotropium.
Conflict of interest statement
Disclosure The authors report no conflicts of interest in this work.
Figures

Similar articles
-
Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Int J Chron Obstruct Pulmon Dis. 2017 Jun 23;12:1877-1882. doi: 10.2147/COPD.S138006. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28694698 Free PMC article. Review.
-
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.Int J Chron Obstruct Pulmon Dis. 2015 Jun 10;10:1093-102. doi: 10.2147/COPD.S72858. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26089659 Free PMC article. Review.
-
Inhaled treatment of COPD: a Delphi consensus statement.Int J Chron Obstruct Pulmon Dis. 2017 Mar 6;12:793-801. doi: 10.2147/COPD.S125564. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28293106 Free PMC article.
-
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30587953 Free PMC article. Review.
-
Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.Int J Chron Obstruct Pulmon Dis. 2018 Mar 5;13:781-792. doi: 10.2147/COPD.S153655. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29551894 Free PMC article.
Cited by
-
Chronic obstructive pulmonary disease phenotypes: imprint on pharmacological and non-pharmacological therapy.Ann Transl Med. 2020 Nov;8(21):1472. doi: 10.21037/atm-20-2219. Ann Transl Med. 2020. PMID: 33313217 Free PMC article. Review.
-
Effect of Nebulized Eucalyptus on Arterial Blood Gases and Physiologic Indexes of Mechanical Ventilated Patients: A Randomized Clinical Trial.J Caring Sci. 2022 Aug 16;11(4):217-223. doi: 10.34172/jcs.2022.20. eCollection 2022 Oct. J Caring Sci. 2022. PMID: 36483688 Free PMC article.
-
Early management of COPD: where are we now and where do we go from here? A Delphi consensus project.Int J Chron Obstruct Pulmon Dis. 2019 Feb 4;14:353-360. doi: 10.2147/COPD.S176662. eCollection 2019. Int J Chron Obstruct Pulmon Dis. 2019. PMID: 30787604 Free PMC article. Review.
-
Bis-Quinolinium Cyclophane Blockers of SK Potassium Channels Are Antagonists of M3 Muscarinic Acetylcholine Receptors.Front Pharmacol. 2020 Sep 16;11:552211. doi: 10.3389/fphar.2020.552211. eCollection 2020. Front Pharmacol. 2020. PMID: 33041794 Free PMC article.
-
Treatment strategies after acute exacerbations of chronic obstructive pulmonary disease: Impact on mortality.PLoS One. 2018 Dec 14;13(12):e0208847. doi: 10.1371/journal.pone.0208847. eCollection 2018. PLoS One. 2018. PMID: 30550602 Free PMC article. Clinical Trial.
References
-
- Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27:397–412. - PubMed
-
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163:1256–1276. - PubMed
-
- European Respiratory Society . European Lung White Book. Huddersfield, UK: ERS; 2003.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases